Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

诺和诺德（Novo Nordisk）日前宣布，美国FDA已批准其重磅疗法Ozempic（司美格鲁肽，semaglutide），用于降低2型糖尿病合并慢性肾病（CKD）成年患者的肾病恶化、肾功能衰竭（终末期肾病）以及心血管疾病导致的死亡风险。根据新闻稿 ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...